FATE
Price
$1.42
Change
-$0.12 (-7.79%)
Updated
Feb 21 closing price
Capitalization
161.73M
9 days until earnings call
TCRX
Price
$2.17
Change
-$0.02 (-0.91%)
Updated
Feb 21 closing price
Capitalization
122.62M
11 days until earnings call
Ad is loading...

FATE vs TCRX

Header iconFATE vs TCRX Comparison
Open Charts FATE vs TCRXBanner chart's image
Fate Therapeutics
Price$1.42
Change-$0.12 (-7.79%)
Volume$2.18M
Capitalization161.73M
TScan Therapeutics
Price$2.17
Change-$0.02 (-0.91%)
Volume$513.67K
Capitalization122.62M
FATE vs TCRX Comparison Chart
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. TCRX commentary
Feb 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and TCRX is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 22, 2025
Stock price -- (FATE: $1.54 vs. TCRX: $2.19)
Brand notoriety: FATE and TCRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 121% vs. TCRX: 668%
Market capitalization -- FATE: $161.73M vs. TCRX: $122.62M
FATE [@Biotechnology] is valued at $161.73M. TCRX’s [@Biotechnology] market capitalization is $122.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $369.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileTCRX’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • TCRX’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than TCRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 4 TA indicator(s) are bullish while TCRX’s TA Score has 5 bullish TA indicator(s).

  • FATE’s TA Score: 4 bullish, 5 bearish.
  • TCRX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, TCRX is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а +21.65% price change this week, while TCRX (@Biotechnology) price change was +7.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.57%. For the same industry, the average monthly price growth was +3.87%, and the average quarterly price growth was +3.11%.

Reported Earning Dates

FATE is expected to report earnings on Apr 30, 2025.

TCRX is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (+4.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($162M) has a higher market cap than TCRX($123M). FATE YTD gains are higher at: -6.364 vs. TCRX (-27.961). TCRX has higher annual earnings (EBITDA): -102.91M vs. FATE (-177.57M). FATE has more cash in the bank: 297M vs. TCRX (271M). TCRX has less debt than FATE: TCRX (90.4M) vs FATE (99M). FATE has higher revenues than TCRX: FATE (13.4M) vs TCRX (9.36M).
FATETCRXFATE / TCRX
Capitalization162M123M132%
EBITDA-177.57M-102.91M173%
Gain YTD-6.364-27.96123%
P/E RatioN/AN/A-
Revenue13.4M9.36M143%
Total Cash297M271M110%
Total Debt99M90.4M110%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
27
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FATETCRX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
73%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Ad is loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HSTXF0.680.06
+9.18%
Heliostar Metals Ltd.
SBGSY53.161.62
+3.14%
Schneider Electric SE
SOUHY11.900.35
+3.03%
South32 Ltd.
FUPBY12.300.08
+0.63%
FUCHS SE
VWSYF13.690.03
+0.22%
Vestas Wind Systems A/S

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-9.65%
ALLO - FATE
58%
Loosely correlated
-13.27%
NTLA - FATE
54%
Loosely correlated
-0.24%
RCKT - FATE
53%
Loosely correlated
-0.46%
NKTX - FATE
50%
Loosely correlated
-6.11%
PRME - FATE
50%
Loosely correlated
-4.72%
More

TCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, TCRX has been loosely correlated with CRVO. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if TCRX jumps, then CRVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TCRX
1D Price
Change %
TCRX100%
+5.29%
CRVO - TCRX
42%
Loosely correlated
+1.09%
IMNM - TCRX
40%
Loosely correlated
+2.12%
SYRE - TCRX
40%
Loosely correlated
+0.18%
FATE - TCRX
39%
Loosely correlated
-9.65%
PRME - TCRX
39%
Loosely correlated
-4.72%
More